A randomized controlled trial of gemcitabine plus cisplatin versus gemcitabine alone in the treatment of metastatic pancreatic cancer

Chao, Yee; Wu, Chen‐Yi; Wang, Jack; Lee, Rheun‐Chuan; Lee, Wei-Ping; Li, Chung–Pin

doi:10.1007/s00280-013-2239-1

Cited by 29 publications

(23 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Firstly, seven duplicates, 192 letters and reviews, 206 non‐human studies, and 180 non‐English studies were excluded from the study, 347 non‐cohort studies, 493 studies unrelated to advanced/metastatic PC, 358 studies unrelated to chemotherapy regimens, and four studies lacking data integrity or no data were excluded from the rest of 1221 studies after full‐text review. Finally, 19 RCTs eligible to the study were included for meta‐analysis (appendix Figure ). These included studies included 5904 patients suffering from advanced/metastatic PC, and a majority of the patients were treated with the Gemcitabine regimen.…”

Section: Resultsmentioning

confidence: 99%

Toxicity of chemotherapy regimens in advanced and metastatic pancreatic cancer therapy: A network meta‐analysis

Wang

Huang

Nie

et al. 2018

J of Cellular Biochemistry

View full text Add to dashboard Cite

This network meta-analysis is adopted in order to compare the toxicity of different chemotherapy regimens in the treatment of advanced/metastatic pancreatic cancer (PC). Randomized controlled trials (RCTs) about different chemotherapy regimens for advanced/metastatic PC were included in this network meta-analysis using Cochrane Library and PubMed electronic databases. The network meta-analysis was performed to combine direct and indirect evidence in order to calculate the odd ratios (OR) and draw a surface under the cumulative ranking (SUCRA) curve. A total of 19 RCTs were enrolled in this network meta-analysis including 12 chemotherapy regimens (Gemcitabine, Gemcitabine + S-1 [tegafur], Gemcitabine + nab-paclitaxel, Gemcitabine + Capecitabine, Gemcitabine + Cisplatin, FOLFIRINOX [oxaliplatin + irinotecan + fluorouracil + leucovorin], Gemcitabine + oxaliplatin, Gemcitabine + irinotecan, Gemcitabine + Exatecan, Gemcitabine + pemetrexed, Gemcitabine + 5-FU, S-1). The incidence of anemia of Gemcitabine + Capecitabine regimen was higher compared with Gemcitabine regimen, Gemcitabine + pemetrexed regimen exhibited the highest incidence rates of anemia and neutropenia; while Gemcitabine + S-1, Gemcitabine + Cisplatin and FOLFIRINOX regimens exhibited the highest incidence rates of neutropenia. However, S-1 regimen exhibited lower incidence rates of leukopenia and thrombocytopenia. Moreover, the incidence rates of nausea/vomiting and rash of Gemcitabine + S-1 regimen were higher compared with Gemcitabine regimen, while Gemcitabine + Cisplatin regimen had the highest incidence rate of nausea/vomiting. This study demonstrated that the hematologic toxicity of S-1 regimen was the lowest, while Gemcitabine regimen exhibited the lowest incidence rate of non-hematologic toxicity, providing guidance for the treatment of advanced/metastatic PC.

show abstract

Section: Resultsmentioning

confidence: 99%

Toxicity of chemotherapy regimens in advanced and metastatic pancreatic cancer therapy: A network meta‐analysis

Wang

Huang

Nie

et al. 2018

J of Cellular Biochemistry

View full text Add to dashboard Cite

show abstract

“…Pancreatic cancer (PC) is one of the leading causes of cancer‐related deaths worldwide with poorest survival rate among common malignancies (Deng et al, ). The majority of patients with developed PC are diagnosed with advanced‐stage or metastatic disease and approximately 50% of new PC cases are diagnosed with metastasis (Chao et al, ). PC undergoes a grim prognosis, with a survival rate lower than 5% over a 5‐year span due to its rapid metastasis and late diagnosis (Luo et al, ).…”

Section: Introductionmentioning

confidence: 99%

Efficacy of different chemotherapy regimens in treatment of advanced or metastatic pancreatic cancer: A network meta‐analysis

Zhang

Liu

et al. 2017

Journal Cellular Physiology

View full text Add to dashboard Cite

We performed a network meta-analysis (NMA) to compare the short- and long-term efficacy of Gemcitabine, Gemcitabine + S-1 (tegafur), Gemcitabine + nab-paclitaxel, Gemcitabine + Capecitabine, Gemcitabine + Cisplatin, FOLFIRINOX (oxaliplatin + irinotecan + fluorouracil + leucovorin), Gemcitabine + oxaliplatin, Gemcitabine + irinotecan, Gemcitabine + Exatecan, Gemcitabine + pemetrexed, Gemcitabine + 5-FU, and S-1 in treating advanced or metastatic pancreatic cancer (PC). The odds radios (OR) or weighted mean difference (WMD) and surface under the cumulative ranking curves (SUCRA) were evaluated by a combination of direct evidence and indirect evidence. In total twenty studies were included in this paper. For short-term efficacy, the overall response rate (ORR) was lower for patients treated with Gemcitabine compared with Gemcitabine + S-1, Gemcitabine + Cisplatin, Gemcitabine + irinotecan and S-1. The ORR for FOLFIRINOX was higher compared with Gemcitabine, Gemcitabine + Capecitabine and Gemcitabine + Cisplatin. The disease control rate (DCR) for Gemcitabine was lower compared with Gemcitabine + S-1, Gemcitabine + Cisplatin, and FOLFIRINOX. For long-term efficacy, the 12-month overall survival (OS) rate for FOLFIRINOX was higher compared with Gemcitabine, Gemcitabine + Capecitabine, Gemcitabine + Cisplatin, Gemcitabine + irinotecan, Gemcitabine + Exatecan, and Gemcitabine + pemetrexed. The SUCRA revealed that FOLFIRINOX was relatively better in both short- and long-term efficacy, while Gemcitabine was relatively poorer. In both short- and long-term efficacy, FOLFIRINOX had the best short- and long-term efficacy among the 12 chemotherapy regimens while efficacy of Gemcitabine was relatively poorer in the treatment of advanced or metastatic PC.

show abstract

“…8 (9)(10)(11)(13)(14)(15)(16). Bu çalışmalarda GP'nin tek başına G'ye oranla daha yüksek cevap oranlarına (10) sahip olduğu gösterilmekle birlikte benzer etkinlikte olduğu da gösterilmiştir (9,11,13 …”

Section: Etkinlik Ve Prognostik Faktörlerunclassified

The efficacy of gemcitabine alone versus gemcitabine plus cisplatin in the treatment of metastatic pancreatic cancer

Erdem¹,

Doğan²,

Güven³

et al. 2018

Acta Oncol Tur.

View full text Add to dashboard Cite

ÖZET GİRİŞ ve AMAÇ:Bu çalışmanın amacı metastatik pankreas kanserinin tedavisinde gemsitabin-sisplatin (GP) kombine kemoterapisine (KT) karşı gemsitabin (G) kemoterapisinin etkinliğini değerlendirmektir. YÖNTEM ve GEREÇLER: Nisan 2005 ile Kasım 2015 tarihleri arasında merkezimizde histopatolojik olarak adenokarsinom tanısı almış metastatik pankreas kanserli hastalarda progresyonsuz sağkalıma (PS) ve genel sağkalıma (GS) etki eden faktörler (klinikopatolojik özellikler, tedaviler, bazal tümör markırları, serum albümin, kreatinin ve bilirubin düzeyleri) retrospektif olarak değerlendirildi. BULGULAR: Üç kür ve üzerinde KT alan toplam 99 hastanın (74 hasta GP, 25 hasta G) yanıt değerlendirmesi yapıldı. Gruplar demografik özellikleri açısından karşılaştırıldığında kombine KT alan hastalar daha genç, daha iyi ECOG performans skoruna ve daha az komorbid hastalığa sahipti. Hastaların %41.4'ü progresyondan sonra ikinci basamak KT almış olup, bu G grubunda %28.0, GP grubunda ise %45.9'du. GP ve G grupları arasında GS farkı saptanmadı (sırasıyla; 8.3 aya karşı 6.0 ay, P=0.13). Ortanca PS GP alan hastalarda G alan hastalara kıyasla daha uzundu (sırasıyla; 5.1 ay ve 3.9 ay, P=0.01) ve bu fark çok değişkenli analizle de doğrulandı. ECOG performans skoru daha iyi (8.3 aya karşı 6.3 ay) ve ikinci basmak KT alan hastalar (12.1 aya karşı 5.9 ay) daha uzun GS ile ilişkili saptandı. TARTIŞMA ve SONUÇ: Gemsitabin-sisplatin tedavisi ile daha iyi PS elde edilirken GS farkı istatiksel olarak anlamlı değildi. Tanı anında ECOG performans durumunu daha iyi ve ikinci basamak KT alabilen hastalar daha iyi genel sağ kalıma sahiptir. Anahtar Kelimeler: Pankreas kanseri, Gemsitabin, Sisplatin ABSTRACT INTRODUCTION: The purpose of this trial was to evaluate the efficacy of gemcitabine (G) alone versus gemcitabine plus cisplatin (GP) in the treatment of metastatic pancreatic cancer. METHODS: In ninety-nine patients with a histopathologically confirmed diagnosis of metastatic pancreatic cancer from April 2005 to December 2015, factors affecting progression-free (PFS) and overall survival (OS) (clinicopathological features, treatments, basal tumor markers, serum albumin, creatinine and bilirubin levels) were retrospectively evaluated. RESULTS: Response evaluations were performed in 99 patients (74 patients for GP group, 25 patients for G group) who received three cycles and more chemotherapy (CT). When the groups were compared in terms of their demographic characteristics, the patients in the group receiving GP were younger with a better performance status and had less comorbid disease. About 41.4% of the patients received second line CT after progression (28.0% in the G group, 45.9% in the GP group). The median OS was 8.3 months in the GP group and 6.0 months in the G group (P=0.13). The median PFS was 5.1 months in the GP group and 3.9 months in the G group (P=0.01). In multivariate analysis, combination CT was associated with longer PFS (5.1 vs. 3.9 months). Patients with a good performance status (8.3 vs. 6.3 months), and those who received se...

show abstract

A randomized controlled trial of gemcitabine plus cisplatin versus gemcitabine alone in the treatment of metastatic pancreatic cancer

Abstract: Gemcitabine alone and G + C had comparable and modest response rates in metastatic pancreatic cancer, but gemcitabine alone produced less toxicities than did G + C.

Cited by 29 publications

References 21 publications

Toxicity of chemotherapy regimens in advanced and metastatic pancreatic cancer therapy: A network meta‐analysis

Toxicity of chemotherapy regimens in advanced and metastatic pancreatic cancer therapy: A network meta‐analysis

Efficacy of different chemotherapy regimens in treatment of advanced or metastatic pancreatic cancer: A network meta‐analysis

The efficacy of gemcitabine alone versus gemcitabine plus cisplatin in the treatment of metastatic pancreatic cancer

Contact Info

Product

Resources

About